



Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course

Citation

Bove, Riley Marie, Elizabeth Secor, Brian Curran Healy, Alexander Musallam, Timothy Vaughan, Bonnie Glanz, Emily Elizabeth Greeke, et al. 2013. Evaluation of an online platform for multiple sclerosis research: Patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS ONE 8(3): e59707.

Published Version

doi:10.1371/journal.pone.0059707

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10622928>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course

Riley Bove^{1,2,3}, Elizabeth Secor¹, Brian C. Healy², Alexander Musallam², Timothy Vaughan⁴, Bonnie I. Glanz², Emily Greeke², Howard L. Weiner^{2,3}, Tanuja Chitnis^{2,3}, Paul Wicks⁴, Philip L. De Jager^{1,2,3,5*}

1 Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Institute for the Neurosciences, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, **2** Department of Neurology, Partners MS Center, Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America, **3** Harvard Medical School, Boston, Massachusetts, United States of America, **4** PatientsLikeMe, Inc., Cambridge, Massachusetts, United States of America, **5** Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America

Abstract

Objectives: To assess the potential of an online platform, PatientsLikeMe.com (PLM), for research in multiple sclerosis (MS). An investigation of the role of body mass index (BMI) on MS disease course was conducted to illustrate the utility of the platform.

Methods: First, we compared the demographic characteristics of subjects from PLM and from a regional MS center. Second, we validated PLM's patient-reported outcome measure (MS Rating Scale, MSRS) against standard physician-rated tools. Finally, we analyzed the relation of BMI to the MSRS measure.

Results: Compared with 4,039 MS Center patients, the 10,255 PLM members were younger, more educated, and less often male and white. Disease course was more often relapsing remitting, with younger symptom onset and shorter disease duration. Differences were significant because of large sample sizes but small in absolute terms. MSRS scores for 121 MS Center patients revealed acceptable agreement between patient-derived and physician-derived composite scores (weighted kappa=0.46). The Walking domain showed the highest weighted kappa (0.73) and correlation ($r_s=0.86$) between patient and physician scores. Additionally, there were good correlations between the patient-reported MSRS composite and walking scores and physician-derived measures: Expanded Disability Status Scale (composite $r_s=0.61$, walking $r_s=0.74$), Timed 25 Foot Walk (composite $r_s=0.70$, walking $r_s=0.69$), and Ambulation Index (composite $r_s=0.81$, walking $r_s=0.84$). Finally, using PLM data, we found a modest correlation between BMI and cross-sectional MSRS ($\rho=0.17$) and no association between BMI and disease course.

Conclusions: The PLM population is comparable to a clinic population, and its patient-reported MSRS is correlated with existing clinical instruments. Thus, this online platform may provide a venue for MS investigations with unique strengths (frequent data collection, large sample sizes). To illustrate its applicability, we assessed the role of BMI in MS disease course but did not find a clinically meaningful role for BMI in this setting.

Citation: Bove R, Secor E, Healy BC, Musallam A, Vaughan T, et al. (2013) Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course. PLoS ONE 8(3): e59707. doi:10.1371/journal.pone.0059707

Editor: Celia Oreja-Guevara, University Hospital La Paz, Spain

Received: November 23, 2012; **Accepted:** February 17, 2013; **Published:** March 20, 2013

Copyright: © 2013 Bove et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: RB is supported by the NIH training grant 5T32AI074549. PLD is a National MS Society Harry Weaver Neuroscience Scholar Award Recipient. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Dr. Vaughan and Dr. Wicks are employed by PatientsLikeMe, Inc. Dr.s Vaughan and Wicks hold stock options in the company. The PatientsLikeMe R&D team has received research support from Abbott, Accordia, Avanir, Biogen, Merck, Novartis, Sanofi, and UCB. PatientsLikeMe provided no financial support to the investigative team from Brigham & Women's Hospital. Dr. Bove and MS Secor report no disclosures. Dr. Healy, Dr. Glanz and Ms. Greeke have received research support from Merck Serono. Dr. Weiner has served as a consultant for Biogen-Idec, EMD Serono, Genentech, GSK, Nasvax, Novartis, and Teva Neurosciences. Dr. Chitnis has served as a consultant for Biogen-Idec, Sanofi Aventis, Novartis, EMD Serono, and Teva Neurosciences, and has received grant support from Merck-Serono for unrelated activities. Dr. De Jager has received research support and speaker honoraria from Biogen-Idec and consultation fees from Teva. He has received research support from Biogen-IDEc, GlaxoSmithKline, and Sanofi-Aventis. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: pdejager@rics.bwh.harvard.edu

Introduction

Investigations of factors associated with progressive disease in multiple sclerosis (MS) have been hampered by the variable and slow course of the disease, a lack of robust biomarkers and the

costs of generating large datasets longitudinally. The emergence of online patient-centered research platforms holds great promise for certain forms of clinical research by providing rapid access to data from large numbers of patients at frequent intervals. However, the

quality and validity of data collected online must be assessed critically.

PatientsLikeMe (www.patientslikeme.com; PLM) is an online platform that includes 29,570 subscribers reporting having MS (as of October 2012). In addition to personal and disease characteristics, individuals also report their disease severity using an MS Rating Scale (MSRS) designed by PLM [1]. Currently, while several validated patient-reported outcome measures of MS disease severity exist, some with online platform experience as in the case of the North American Research Committee on Multiple Sclerosis (NARCOMS) [2–4], there is no “gold standard” for data capture through online platforms. The MSRS has previously undergone psychometric validation and shown high internal consistency, concordant validity with the NARCOMS Patient-Derived Disease Step, and demonstrated adequate known-groups validity. The instrument has been made available for free by PatientsLikeMe under Creative Commons license [1].

To determine the potential and limitations of this platform for future investigations, our study aimed first to determine whether PLM members reporting MS were comparable to patients with MS followed at a large regional MS referral center. Then, the MSRS was validated in a clinical setting. Finally, the potential of this platform was tested by assessing the role of body mass index (BMI), a risk factor for MS [5–7], on disease course, a phase of the disease for which limited data exist in this context [8].

Methods

I. Comparison of Demographic and Disease Characteristics of PLM Members with Patients from the Partners Multiple Sclerosis Center

Subjects. PLM is an online research platform based in Cambridge, Massachusetts, designed to allow patients to share data about their conditions, treatments, symptoms and comorbidities through structured data collection [9], but with some features of an online social network. Members join the site with the explicit understanding that any data provided will be shared anonymously but openly, including with pharmaceutical manufacturers, from which the company derives its funding. Use of the system has been associated with positive measures of patient literacy, communication and support [10], with development of other patient-reported outcomes [11–13], and with clinical insights [14]. From the over 29,570 members of PLM reporting a diagnosis of MS, members aged 18 and above were selected if (1) they provided at least 4 of the 5 following baseline characteristics: age, sex, disease type, age at first symptom, age at diagnosis; and (2) they had updated their profiles at least twice between 1/1/2009 and 8/31/2011 ($n = 10,255$). Both demographic (age, race, ethnicity, gender, family history of MS, education) and disease characteristics (disease type, age at first symptoms, use of disease modifying therapy (DMT)) were obtained from the PLM databases.

The Partners MS Center (Brigham and Women’s Hospital) is a regional MS referral center in the Northeastern United States. Detailed electronic records of patient visits to the Center are captured using structured encounter forms and stored within an Oracle software-based relational database designed to follow the longitudinal histories of patients with demyelinating diseases. Data derived from this cohort have been extensively described [15]. We included all subjects aged 18 or older, with an MS diagnosis by 2005 McDonald Criteria, who were evaluated clinically at least twice at the Partners MS Center since 1/1/2009 ($n = 4,039$). IRB approval was obtained for the analysis of the existing PLM and Partners data from the Partners Healthcare Human Research Committee, our Institutional Review Board. Given the consent

documents governing the use of the Partners MS center data, we could not determine whether any MS Center patients were also members of PLM.

Statistical analysis. T-tests were used for continuous outcomes and chi-squared analyses were used for categorical outcomes. Identical analyses were performed for subsets of patients treated with glatiramer acetate and interferons. Due to missing data for certain individuals, percentages for each variable were calculated based on a different sample sizes.

II. Validation of the Patient-reported MSRS

Subjects. Patient- and physician-derived MSRS scores were compared for a sample of MS patients seen at the Partners MS Center over 20 days in November 2011. All patients aged 18 or older, who carried a diagnosis of MS based on 2005 McDonald Criteria by an MS Center physician, were fluent in English, and who presented for routine neurological follow up at the Partners MS Center were approached. IRB approval was obtained from the Partners Healthcare Human Research Committee. Verbal informed consent was obtained from participants, in compliance with the IRB, because it was determined that the research presented no more than minimal risk of harm to subjects and involved no procedures for which written consent is normally required outside the research context. A study fact sheet describing the study was provided with the questionnaire to each patient approached, in compliance with the IRB. Thus only consenting individuals would complete the questionnaire, and blank questionnaires would be stored for those who did not consent. None of the 162 patients who were approached refused participation. Of these patients, 34 were unable to participate due to the constraints of the MS Center schedule for clinical encounters. In addition, 7 patients who filled out the questionnaire did not have a definite MS diagnosis. This resulted in 121 subjects and their physician completing an MSRS evaluation.

MSRS score. In this 7-item questionnaire, patients rate their disability on a 0–4 scale in 7 areas (walking, use of upper extremities, speech disturbance, vision, dysphagia, cognitive or affective disturbance, and sensory disturbance). Total scores range from 0–28 (**Table S1**).

Clinical assessment. Patients completed the MSRS independently of the physician prior to the clinical encounter. Following the clinical encounter, each patient’s physician then completed the MSRS form, which covers functions routinely assessed and logged in the Oracle database, and then provided scores for the Expanded Disability Status Scale (EDSS) [16], Ambulation Index (AI [17]) and Timed 25 foot walk (T25FW [18]).

Statistical analysis. For comparisons of patient- and physician-derived MSRS scores, a weighted kappa statistic was calculated for each MSRS domain, as well as for the composite (sum) score to assess the agreement between the two raters. For the composite score, a Bland-Altman plot for the patient and physician score was also created. In addition, Spearman’s correlation coefficient was also calculated to assess the level of association between the two raters. Finally, the proportion of agreement between physician and patient was calculated for each MSRS domain, and reason for lack of concordance (physician rates score higher, vs. patient rates score higher) was recorded. Nonparametric Spearman correlation coefficients were also calculated between EDSS, T25FW, and AI and both patient- and physician-derived MSRS composite and walking domain subscores. This allowed us to assess the criterion validity (the extent to which the measure of interest corresponds with an

existing external criterion [19]) of the MSRS walking domain subscore.

III. Investigation of BMI on MS Disease Course in PLM

Subjects. PLM members were selected in an identical manner to (I), but with profiles updated at least twice between 1/1/2009 and 1/1/2012 ($n = 10,433$). IRB approval was obtained for analysis of these existing PLM data from the Partners Healthcare Human Research Committee.

Body mass index. Self-reported height, weight, and calculated BMI (kg/m^2) were included for all PLM subjects in the study. The following measurements were excluded: height <55 or >85 inches, weight <70 or >540 lbs, and BMI >190 .

Statistical analysis. BMI was first classified according to WHO criteria to examine the distribution of this parameter in our sample: underweight ($<18.50 \text{ kg}/\text{m}^2$), normal weight ($18.50\text{--}24.99 \text{ kg}/\text{m}^2$), overweight ($25.00\text{--}29.99 \text{ kg}/\text{m}^2$), and obese ($\geq 30.00 \text{ kg}/\text{m}^2$). Then, a cross-sectional analysis was performed correlating continuous BMI at most recent data entry point with MSRS composite score, using nonparametric correlations and adjusting for age, sex, race, disease duration, and disease type. Third, to assess the impact of BMI on longitudinal accumulation of disability (MSRS), we used two mixed models with random slopes and intercepts and robust standard errors to estimate the interaction between BMI and follow-up time, controlling for age, sex, race, disease duration, and disease type, and the interaction between disease type and follow-up time. In the first model, the predictor of interest was the earliest BMI available for each subject after symptom onset. In the second model, the predictor of interest was BMI within the first three months of symptom onset, which was available for a subset of subjects.

Only de-identified PLM data were transferred to the Brigham and Women's Hospital research team for quality control and analysis. All statistical analyses were performed using either the R version 2.14.2 (www.r-project.org) or SAS Software (Version 9.3).

Results

I. Comparison of Subject and Disease Characteristics between PLM Members and Partners MS Center Subjects

In comparing how an online patient population recruited at a national level (PLM members) relates to a patient population found at a large regional MS center (the Boston-based Partners MS Center patient population), we found small (in absolute terms) but statistically significant differences for all tested variables ($p < 0.0001$ for all comparisons, **Table 1**). Specifically, PLM members were younger, more educated, more often female, and less often white. Further, the reported disease course of PLM members was more often relapsing remitting, with younger age at symptom onset and shorter disease duration. A family history of MS was also less common among PLM members. Similar proportions of PLM and MS Center subjects used glatiramer acetate (24% vs. 25%), but more PLM subjects used interferon beta (29% vs. 18%). For both treatment groups, the differences in demographic characteristics between the MS Center and PLM populations were similar to those reported between the MS Center and the complete PLM population examined (**Table S2**).

II. Validation of Patient Reported MSRS

To assess the validity of the patient reported MSRS instrument deployed in PLM's online platform, we administered this instrument to 121 MS patients at the Partners MS Center, with comparable demographic and disease characteristics to the entire MS Center population described in **Table 1** (**Table S3**), and

Table 1. Comparison of PLM members' individual and disease characteristics with those of patients followed at the Partners MS Center.

Variable	PLM	MS Center	Comparison
	N = 10255	N = 4039	p-value
	Mean (SD)	Mean (SD)	
Current Age, yrs	44.8 (10.6)	47.8 (12.0)	<0.0001
Age at first symptom, yrs	32.8 (10.0)	34.2 (10.8)	<0.0001
Disease Duration, yrs	12.0 (9.3)	13.7 (10.5)	<0.0001
	%	%	
Gender (% F)	80.1	74.8	<0.0001
Family History of MS (% yes)	22.4	25.5	0.0002
Race			<0.0001
White	90.4	92.4	
African American	5.1	4.6	
Other	4.5	3.0	
MS course			<0.0001
Relapsing-remitting	77.6	70.2	
Secondary progressive	12.0	22.6	
Primary progressive	7.3	6.2	
Progressive relapsing	3.1	1.0	
Education Level			<0.0001
Less than 12 years	2.2	2.5	
Completed High School	14.7	16.9	
Some College	42.2	54.8	
Completed College	25.8	12.2	
Post Graduate	15.1	13.6	

NB. For individual variables, as some subjects had missing data, the N used for calculation of percentages was lower than the total N of respondents.
doi:10.1371/journal.pone.0059707.t001

with the spectrum of disability seen at our Center (median EDSS: 2, range: 0–8.5).

Good agreement between the patient- and physician-derived composite MSRS scores was observed (weighted kappa = 0.43, **Table 2**; **Figure S1**). The two scores were strongly correlated (Spearman rank-order correlation coefficient, $r_s = 0.693$). When we examined individual domains, the walking score had the highest level of agreement (weighted kappa = 0.732) and the highest level of correlation ($r_s = 0.856$). There was also good agreement and association for upper extremity weakness and swallowing (weighted kappa >0.4 , $r_s > 0.5$). The other four domains had lower levels of agreement between physician and patient assessments but all were significantly correlated ($p < 0.0001$). The relationships between the patient and physician scores for each domain are shown in **Table 2** and **Table S4a–g**. There did not appear to be any systematic under- or over-reporting of symptoms by either patients or physicians, as evidenced by the percentages of patients vs. physicians providing a higher score (**Table 2**).

When we compared physician-derived MSRS scores with disease severity measures routinely captured at the Partners MS Center, there was good correlation between the composite MSRS and EDSS ($r_s = 0.838$, $N = 117$), Timed 25 foot walk (T25FW) ($r_s = 0.703$, $N = 98$), and ambulation index (AI) ($r_s = 0.813$, $N = 107$). In terms of subdomains, the MSRS walking domain

Table 2. Comparison of patient- and physician- scored MSRS.

Domain	AGREEMENT BETWEEN PATIENT AND PHYSICIAN (% Scores)			Weighted kappa statistic (95% CI)	Correlation	
	Patient rated higher	Perfect Agreement	Patient rated lower		Spearman r	p-value
Walking	20.0	62.5	17.5	0.730 (0.652, 0.807)	0.856	<0.0001
Arms	22.5	61.7	15.8	0.479 (0.341, 0.617)	0.552	<0.0001
Vision	23.3	56.7	20.0	0.342 (0.198, 0.486)	0.426	<0.0001
Speech	10.0	79.2	10.8	0.307 (0.115, 0.500)	0.367	<0.0001
Swallowing	8.3	85.0	6.7	0.419 (0.210, 0.627)	0.506	<0.0001
Cognitive	27.1	45.8	27.1	0.338 (0.205, 0.471)	0.446	<0.0001
Sensory	37.0	41.2	21.8	0.320 (0.196, 0.443)	0.414	<0.0001
Composite Score	47.5	16.9	35.6	0.462 (0.363, 0.554)	0.693	<0.0001

doi:10.1371/journal.pone.0059707.t002

demonstrated a similar level of correlation with EDSS ($r_s = 0.807$), T25FW ($r_s = 0.693$), and AI ($r_s = 0.840$) ($p < 0.001$ for all). We also compared patient-derived MSRS composite scores with physician-derived clinical scales; while the correlations were weaker, these remained highly significant ($p < 0.001$): EDSS ($r_s = 0.609$), T25FW ($r_s = 0.497$), and AI ($r_s = 0.591$). Correlations with the MSRS walking domain score were somewhat stronger: EDSS ($r_s = 0.738$), T25FW ($r_s = 0.650$), and AI ($r_s = 0.738$).

III. Investigation of BMI and Disease Course

Having established the clinical relevance of the MSRS, we analyzed prospectively collected data from PLM members to assess the role of BMI in disease severity, as assessed by self-reported MSRS. At last data entry, the mean BMI among PLM members was 27.6 kg/m² ($n = 10,433$), with 25.7% subjects who were overweight (BMI > 24.9) and 26.7% subjects who were obese (BMI > 29.9) (**Table 3**).

Cross-sectionally, we noted a very modest correlation ($\rho = 0.17$, $n = 1336$) between greater BMI (continuous variable) and greater MSRS (**Table 4**). While significant because of the large sample size ($p < 0.001$), the magnitude of this correlation is sufficiently small that it is unlikely to be of clinical relevance. Using a mixed model approach, we also assessed whether, in patients who have MS, BMI at a given time affects the subsequent trajectory of disease severity as assessed by repeated MSRS measures. In this analysis of prospectively collected MSRS, we did

not see an effect of BMI on MSRS trajectory (estimate (95% CI) = 0.0133 (−0.00013, 0.0267), $p = 0.05$, $n = 1695$), after adjusting for disease duration, age, sex, race, disease type, and the interaction between disease type and follow-up time. When available ($n = 236$), we also assessed the relation of reported BMI at symptom onset with subsequent MSRS trajectory, and we also found no effect of BMI at symptom onset with subsequent disease course (estimate (95% CI) = 0.0137 (−0.0162, 0.0436), $p = 0.37$, $n = 236$). Overall, these longitudinal analyses – along with the cross-sectional analysis – suggest that BMI does not have a strong effect on MS disease severity as estimated by the self-reported MSRS instrument.

Discussion

In this study, we report good correlation of the patient-reported MSRS measure developed by PLM with standard clinical assessment measures used in MS, such as the EDSS. The availability of this online instrument and of the large PLM membership provides a useful, complementary platform for MS clinical research. It does not replace rigorous, prospective cohort studies or targeted clinical research projects performed in academic MS centers; instead, it offers a different option, that has an opportunity to leverage the frequent sampling of data from a large subject population.

While we found small demographic differences between PLM members with recent profile updates and patients at our MS center, they were modest in absolute terms. It should be noted that both sets of subjects represent somewhat biased subsets of the overall MS patient population; this limitation is somewhat mitigated by their large sample size but needs to be clearly stated. Interestingly, the differences that we describe between the patient populations we compared – including that PLM members had a younger age, higher education, larger proportion of women and lower proportion of self-reported white non-Hispanic origin – are slightly at odds with other demographic surveys of users of online tools, that have noted greater use and more frequent use by individuals who are white, female, older, with higher incomes, with good internet skills, and who are not employed [20]. We limited our comparative analysis to the subset of PLM members with recent profile updates, in order to examine active members who are likely to participate in ongoing online investigations; however, it is possible that these individuals differ in demographic terms from the general PLM population. The greater proportion

Table 3. Distribution of self-reported BMI in the PLM population.

BMI Distribution	Within 3 months of first symptom	Last data entry
N	1173	10433
Underweight	42 (3.6%)	330 (3.2%)
Normal	476 (40.6%)	4058 (38.9%)
Overweight	313 (26.7%)	2970 (28.5%)
Obese	342 (29.2%)	3075 (29.5%)
Mean (SD)	27.36 (6.78)	27.56 (6.78)
Median	25.84	26.2

doi:10.1371/journal.pone.0059707.t003

Table 4. Cross-sectional and longitudinal associations of BMI with disease severity, as measured by the MSRS.

	statistic	p-value
Cross-sectional association		
Adjusted Spearman correlation between BMI at last data entry and MSRS (N = 6229)*	Adjusted $r = 0.14$	<0.001
Longitudinal association		
Interaction term between BMI within 3 months of symptom onset and follow-up time (N = 236)**	Estimate = 0.0137 95% CI = -0.0162, 0.0436	0.37
Interaction term between BMI at first data entry and follow-up time (N = 1695)**	Estimate = 0.0133 95% CI = -0.00013, 0.0267	0.05

*All models adjusted for current age, sex, disease duration (years), disease course, and race.

**Models also adjusted for interaction between disease type and follow-up time.

doi:10.1371/journal.pone.0059707.t004

of interferon beta-treated PLM members may partially reflect the fact that they had more relapsing onset disease. We also compared the PLM population to the 31,232 respondents from NARCOMS, a large and well-described registry-based cohort [21,22] (**Table S5**). Here, we found statistically significant but small absolute differences in demographic characteristics, further suggesting that the PLM members, offer a reasonable alternative platform for MS clinical research that could yield insights that are generalizable to other MS populations after appropriate control for confounders.

In this study, we explored the use of PLM to answer a timely clinical question in which the current literature offers conflicting results: the relationship between excess body weight and MS disease course in the North American population that is becoming increasingly heavier. Obesity in an individual's mother [23] or during adolescence of the individual [5,6] may increase the risk for MS and perhaps for a relapsing onset [7]. However, in adulthood, insofar as it is possible to disentangle the effects of age, disability and comorbidities, individuals with MS may have lower body mass index (BMI) than age-matched controls [8,24–27]. Only one prior study, by the North American Research Committee on Multiple Sclerosis (NARCOMS), examined longitudinal data and suggested that fluctuations in BMI are not associated with changes in disease severity as measured by Patient-determined disease steps [8]. Here, using a large sample size and prospectively collected data, we report consistent results suggesting that there is no evidence for increased BMI having a strong effect on disability in MS: we noted a very modest correlation between BMI and MSRS in the cross-sectional analysis ($\rho = 0.17$, $n = 1336$) and only a nominally significant association in the analysis of the longitudinal MSRS data (estimate (95% CI) = 0.0133 (-0.00013, 0.0267)), suggesting that there is no clinically meaningful role for BMI in disability for MS in most individuals. Individuals do tend to under-estimate their BMI in self-reports [28]; however, because we examined BMI as a continuous variable this under-estimation should not influence the statistical estimate of this relationship on longitudinal course. However, we cannot exclude the possibility that BMI may have a very weak effect on the accumulation of disability, that it may influence other measures of disability in MS or that it may have a role in a subset of individuals. Further, the adverse health consequences of high BMI are well documented and doubtlessly impact the life course of MS patients [7], irrespective of a direct effect of BMI on MS disability.

Our findings and those of others relating BMI and disease severity in adults [8], contrast with the increased risk of MS associated with higher BMI during adolescence noted in prior studies [5,6], possibly through immunologic modulation by hormones such as leptin and adiponectin [29–32]. This disjunction of a risk factor's role in susceptibility and disease course has been

suggested for other susceptibility factors such as EBV infection [33] and genetic risk factors [34], but not for cigarette smoking [35,36] and vitamin D levels [37], which may influence both disease susceptibility and disease course. Additionally, because high BMI is associated with low vitamin D status, the association between BMI and risk of MS may in fact be confounded by vitamin D status [38]. As we better understand the functional consequences of these various risk factors, we may begin to see how they influence downstream molecular events leading to MS onset and/or disability.

There are challenges and limitations to online research platforms, including biases arising from the digital divide, issues of privacy, autonomy and data storage, variable and inconsistent data sampling schedules, and lack of objective validation of reported data such as height and weight [39,40]. Also, in the absence of a gold standard for patient reported outcomes, it is not feasible to determine whether the physician or patient is “right”, only to understand the broader areas of agreement and discordance. For example, a patient may be more aware of sensory disturbances, but a clinician may better appreciate the broader range of gait disturbance seen in clinical practice. In this study a bias towards greater MSRS agreement between provider and patient may have existed, as the provider relied on the patient during the clinical interview to answer some questions, such as those pertaining to swallowing. Also, as with any clinical instrument, test-retest reliability is critical to enable powerful analysis; while we did not assess this feature of the MSRS as part of our study, the reliability of the MSRS has been previously evaluated and revealed one-week test-retest correlations of $r = 0.91$ ($p < 0.001$) [1]. While not as comprehensive as a clinical examination or as biomedically grounded as an MRI scan, a patient reported outcome of disability such as the MSRS has the advantage of being rapid and free to administer; it also has the potential to enable patients themselves to learn more about the progression of their illness through self-monitoring. Further, missing data and incomplete participation by many members are important limitations that require rigorous quality control measures such as the ones that we implemented. In this study, from an initial 28,025 members reporting at least some information pertaining to MS, limiting the analysis to subjects with at least two separate dates of data entry in the study period and implementing the other quality measures reduced the analysis to a final N of 10,255 subjects. Finally, because online platforms are relatively new, the follow up time may not yet be sufficient long to detect clinically meaningful changes in the MSRS.

In conclusion, online research remains in its infancy and continues to pose ethical and methodological challenges. Nonetheless, the opportunity of capturing an assessment of disability on

a very frequent basis opens exciting new possibilities that are not possible using more episodic data collection strategies such as those collected by NARCOMS. Prospective tracking of symptoms in “real time” may eventually allow researchers to assess whether certain symptoms such as increases in fatigue or fluctuations in “brain fog” can serve as harbingers for clinical attacks or be useful in assessing a patient’s clinical trajectory or response to disease-modifying therapy. The PLM member population therefore offers an intriguing new platform for MS investigations. Its results, after appropriate consideration of potential demographic and other confounders, may be generalizable to and replicable in the larger patient population seen in large MS centers.

Supporting Information

Figure S1 Bland-Altman plot for Patient and Physician Total MSRS scores.

(DOCX)

Table S1 Illustration: The Multiple Sclerosis Related Severity (MSRS) questionnaire.

(DOCX)

Table S2 Comparison of patient and disease characteristics for patients treated with glatiramer acetate and interferons.

(DOCX)

References

- Wicks P, Vaughan TE, Massagli MP (2012) The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community. *Health and quality of life outcomes* 10: 70.
- Schwartz CE, Sprangers MA, Oort FJ, Ahmed S, Bode R, et al. (2011) Response shift in patients with multiple sclerosis: an application of three statistical techniques. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation* 20: 1561–1572.
- Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ (2009) The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). *Multiple sclerosis* 15: 1092–1102.
- Twiss J, Doward LC, McKenna SP, Eckert B (2010) Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). *Health and quality of life outcomes* 8: 117.
- Munger KL, Chitnis T, Ascherio A (2009) Body size and risk of MS in two cohorts of US women. *Neurology* 73: 1543–1550.
- Hedstrom AK, Olsson T, Alfredsson L (2012) High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. *Multiple sclerosis*.
- Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T (2011) Association between comorbidity and clinical characteristics of MS. *Acta neurologica Scandinavica* 124: 135–141.
- Salter AR, Marrie RA, Tyry T, Cofield SS, Fox R, et al. Is weight associated with disability in a 6-year period as assessed in the NARCOMS Registry?; 2011; Amsterdam.
- Brownstein CA, Brownstein JS, Williams DS, 3rd, Wicks P, Heywood JA (2009) The power of social networking in medicine. *Nature biotechnology* 27: 888–890.
- Wicks P, Keininger DL, Massagli MP, la Loge CD, Brownstein C, et al. (2011) Perceived benefits of sharing health data between people with epilepsy on an online platform. *Epilepsy & behavior: E&B*.
- Wicks P, Vaughan TE, Massagli MP, Heywood J (2011) Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. *Nature biotechnology* 29: 411–414.
- Wicks P, Frost J (2008) ALS patients request more information about cognitive symptoms. *European journal of neurology: the official journal of the European Federation of Neurological Societies* 15: 497–500.
- Turner MR, Wicks P, Brownstein CA, Massagli MP, Toronjo M, et al. (2011) Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. *Journal of neurology, neurosurgery, and psychiatry* 82: 853–854.
- Wicks P, Massagli M, Kulkarni A, Dastani H (2011) Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). *Journal of medical Internet research* 13: e12.
- Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T (2011) Demographic and clinical characteristics of malignant multiple sclerosis. *Neurology* 76: 1996–2001.
- Kurtzke J (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* 33: 1444–1452.
- Hauser SL, Dawson DM, Leirich JR, Beal MF, Kevy SV, et al. (1983) Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. *The New England journal of medicine* 308: 173–180.
- Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. *National MS Society Clinical Outcomes Assessment Task Force. Multiple sclerosis* 5: 244–250.
- Marrie RA, Goldman M (2007) Validity of performance scales for disability assessment in multiple sclerosis. *Multiple sclerosis* 13: 1176–1182.
- Mathew M, Morrow JR, Frierson GM, Bain TM (2011) Assessing digital literacy in web-based physical activity surveillance: the WIN study. *American journal of health promotion: AJHP* 26: 90–95.
- Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T (2007) Validation of the NARCOMS registry: diagnosis. *Multiple sclerosis* 13: 770–775.
- Buchanan RJ, Chakravorty BJ, Tyry T, Hatcher W, Vollmer T (2009) Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristics. *NeuroRehabilitation* 25: 271–278.
- Gardener H, Munger KL, Chitnis T, Michels KB, Spiegelman D, et al. (2009) Prenatal and perinatal factors and risk of multiple sclerosis. *Epidemiology* 20: 611–618.
- Nortvedt MW, Riise T, Maeland JG (2005) Multiple sclerosis and lifestyle factors: the Hordaland Health Study. *Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 26: 334–339.
- Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R (1998) Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. *International journal of epidemiology* 27: 845–852.
- Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. (2009) Comorbidity delays diagnosis and increases disability at diagnosis in MS. *Neurology* 72: 117–124.
- Khurana SR, Bamer AM, Turner AP, Wadhvani RV, Bowen JD, et al. (2009) The prevalence of overweight and obesity in veterans with multiple sclerosis. *American journal of physical medicine & rehabilitation/Association of Academic Physiatrists* 88: 83–91.
- Gorber SC, Tremblay M, Moher D, Gorber B (2007) A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. *Obesity reviews: an official journal of the International Association for the Study of Obesity* 8: 307–326.
- Musabak U, Demirkaya S, Genc G, Illici RS, Odabasi Z (2011) Serum adiponectin, TNF-alpha, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. *Neuroimmunomodulation* 18: 57–66.
- Matarese G, Carrieri PB, Montella S, De Rosa V, La Cava A (2010) Leptin as a metabolic link to multiple sclerosis. *Nature reviews Neurology* 6: 455–461.
- Hietaharju A, Kuusisto H, Nieminen R, Vuolteenaho K, Elovaara I, et al. (2010) Elevated cerebrospinal fluid adiponectin and adipisin levels in patients with multiple sclerosis: a Finnish co-twin study. *European journal of neurology: the*

- official journal of the European Federation of Neurological Societies 17: 332–334.
32. Kraszula L, Jasinska A, Eusebio MO, Kuna P, Glabinski A, et al. (2012) Evaluation of the relationship between leptin, resistin, adiponectin and natural regulatory T cells in relapsing-remitting multiple sclerosis. *Neurologia i neurochirurgia polska* 46: 22–28.
 33. Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, et al. (2011) Epstein-Barr virus and multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry* 82: 1142–1148.
 34. Consortium IMMSG (2011) Genome-wide association study of severity in multiple sclerosis. *Genes and immunity* 12: 615–625.
 35. Wingerchuk DM (2012) Smoking: effects on multiple sclerosis susceptibility and disease progression. *Therapeutic advances in neurological disorders* 5: 13–22.
 36. Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, et al. (2009) Smoking and disease progression in multiple sclerosis. *Archives of neurology* 66: 858–864.
 37. Munger KL, Ascherio A (2011) Prevention and treatment of MS: studying the effects of vitamin D. *Multiple sclerosis* 17: 1405–1411.
 38. Turer CB, Lin H, Flores G (2013) Prevalence of Vitamin D Deficiency Among Overweight and Obese US Children. *Pediatrics* 131: e152–161.
 39. Buchanan EA, Hvizdak EE (2009) Online survey tools: ethical and methodological concerns of human research ethics committees. *Journal of empirical research on human research ethics: JERHRE* 4: 37–48.
 40. Cantrell MA, Lupinacci P (2007) Methodological issues in online data collection. *Journal of advanced nursing* 60: 544–549.